Header Logo

Connection

CHARLES WYKOFF to Middle Aged

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Middle Aged.
CHARLES WYKOFF
Connection Strength
2.004
Middle Aged
  1. Morphologic Stages of Full-Thickness Macular Hole on Spectral-Domain OCT. Ophthalmol Retina. 2025 Apr; 9(4):305-313.
    View in: PubMed
    Score: 0.060
  2. CLINICALLY RELEVANT POSTERIOR VITREOUS DETACHMENT STAGING USING CIRCUMPAPILLARY AND MACULAR VOLUME OPTICAL COHERENCE TOMOGRAPHY. Retina. 2024 08 01; 44(8):1441-1448.
    View in: PubMed
    Score: 0.059
  3. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
    View in: PubMed
    Score: 0.057
  4. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.
    View in: PubMed
    Score: 0.049
  5. Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis. Can J Ophthalmol. 2023 06; 58(3):252-261.
    View in: PubMed
    Score: 0.049
  6. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2021 Jun; 27(6):743-752.
    View in: PubMed
    Score: 0.047
  7. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
    View in: PubMed
    Score: 0.047
  8. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. Am J Ophthalmol. 2021 06; 226:126-136.
    View in: PubMed
    Score: 0.046
  9. Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization. Ophthalmol Retina. 2021 04; 5(4):348-356.
    View in: PubMed
    Score: 0.045
  10. Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. Ophthalmol Retina. 2021 03; 5(3):224-233.
    View in: PubMed
    Score: 0.044
  11. Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice. Am J Ophthalmol. 2020 07; 215:66-71.
    View in: PubMed
    Score: 0.044
  12. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. Ophthalmol Retina. 2019 12; 3(12):1076-1086.
    View in: PubMed
    Score: 0.042
  13. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA?Study. Ophthalmology. 2019 08; 126(8):1171-1180.
    View in: PubMed
    Score: 0.041
  14. Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes. Graefes Arch Clin Exp Ophthalmol. 2019 May; 257(5):883-889.
    View in: PubMed
    Score: 0.040
  15. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):692-697.
    View in: PubMed
    Score: 0.039
  16. Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial. Ophthalmic Surg Lasers Imaging Retina. 2018 04 01; 49(4):258-264.
    View in: PubMed
    Score: 0.038
  17. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol. 2018 05; 102(5):631-636.
    View in: PubMed
    Score: 0.036
  18. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 04; 102(4):460-464.
    View in: PubMed
    Score: 0.036
  19. THE ASSOCIATION OF EPIRETINAL MEMBRANE WITH MACULAR HOLE FORMATION AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR. Retina. 2017 Jun; 37(6):1073-1078.
    View in: PubMed
    Score: 0.036
  20. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 Aug; 180:8-17.
    View in: PubMed
    Score: 0.036
  21. Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. Ophthalmology. 2017 06; 124(6):919-921.
    View in: PubMed
    Score: 0.035
  22. Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes. Ophthalmology. 2017 05; 124(5):583-595.
    View in: PubMed
    Score: 0.035
  23. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology. 2017 04; 124(4):440-449.
    View in: PubMed
    Score: 0.035
  24. Diagnostic and Therapeutic Challenges. Retina. 2016 Nov; 36(11):2239-2245.
    View in: PubMed
    Score: 0.034
  25. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017 Jan; 173:56-63.
    View in: PubMed
    Score: 0.034
  26. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2016 Jul; 36(7):1349-56.
    View in: PubMed
    Score: 0.034
  27. Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. Ophthalmology. 2016 08; 123(8):1716-1721.
    View in: PubMed
    Score: 0.033
  28. GRANULAR HYPERREFLECTIVE SPECKS BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS SIGNS OF WEST NILE VIRUS INFECTION: THE STARDUST SIGN. Retin Cases Brief Rep. 2016; 10(4):349-53.
    View in: PubMed
    Score: 0.033
  29. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015 Dec; 122(12):2514-22.
    View in: PubMed
    Score: 0.032
  30. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
    View in: PubMed
    Score: 0.031
  31. Progressive retinal nonperfusion in ischemic central retinal vein occlusion. Retina. 2015 Jan; 35(1):43-7.
    View in: PubMed
    Score: 0.030
  32. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul; 98(7):951-5.
    View in: PubMed
    Score: 0.029
  33. Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital (2002-2009). Am J Ophthalmol. 2010 Sep; 150(3):392-398.e2.
    View in: PubMed
    Score: 0.022
  34. Fovea-sparing retinal detachments: time to surgery and visual outcomes. Am J Ophthalmol. 2010 Aug; 150(2):205-210.e2.
    View in: PubMed
    Score: 0.022
  35. Intraocular cryptococcoma. Arch Ophthalmol. 2009 May; 127(5):700-2.
    View in: PubMed
    Score: 0.020
  36. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology. 2008 Sep; 115(9):1501-7, 1507.e1-2.
    View in: PubMed
    Score: 0.019
  37. Myopic laser in situ keratomileusis in eyes with thick corneas. J Cataract Refract Surg. 2006 May; 32(5):900-1.
    View in: PubMed
    Score: 0.017
  38. Progressive inner retinal neurodegeneration in non-proliferative macular telangiectasia type 2. Br J Ophthalmol. 2025 Feb 24; 109(3):401-407.
    View in: PubMed
    Score: 0.015
  39. MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2025 Feb; 132(2):131-140.
    View in: PubMed
    Score: 0.015
  40. Risk factors for development of hyper-reflective foci overlying drusen in eyes with intermediate age-related macular degeneration. Br J Ophthalmol. 2024 Aug 22; 108(9):1234-1239.
    View in: PubMed
    Score: 0.015
  41. Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy. Can J Ophthalmol. 2025 Apr; 60(2):91-99.
    View in: PubMed
    Score: 0.015
  42. MANAGEMENT OF LARGE FULL-THICKNESS MACULAR HOLES: Long-Term Outcomes of Internal Limiting Membrane Flaps and Internal Limiting Membrane Peels. Retina. 2024 07 01; 44(7):1165-1170.
    View in: PubMed
    Score: 0.015
  43. Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A Cross Sectional Study. Ophthalmol Retina. 2024 Sep; 8(9):854-862.
    View in: PubMed
    Score: 0.014
  44. Predictive Factors Influencing the Evolution of Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration Eyes. Ophthalmol Retina. 2024 Sep; 8(9):863-871.
    View in: PubMed
    Score: 0.014
  45. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 03 23; 403(10432):1153-1163.
    View in: PubMed
    Score: 0.014
  46. Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial. Ocul Immunol Inflamm. 2024 Oct; 32(8):1556-1563.
    View in: PubMed
    Score: 0.014
  47. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 12 01; 141(12):1152-1160.
    View in: PubMed
    Score: 0.014
  48. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023 10 21; 402(10411):1434-1448.
    View in: PubMed
    Score: 0.014
  49. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 10 21; 402(10411):1449-1458.
    View in: PubMed
    Score: 0.014
  50. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 10 01; 140(10):946-954.
    View in: PubMed
    Score: 0.013
  51. NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study. Retina. 2022 03 01; 42(3):426-433.
    View in: PubMed
    Score: 0.012
  52. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies. Retina. 2022 03 01; 42(3):511-518.
    View in: PubMed
    Score: 0.012
  53. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 01; 139(9):946-955.
    View in: PubMed
    Score: 0.012
  54. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. Retina. 2020 Nov; 40(11):2175-2183.
    View in: PubMed
    Score: 0.011
  55. Automated vessel density detection in fluorescein angiography images correlates with vision in proliferative diabetic retinopathy. PLoS One. 2020; 15(9):e0238958.
    View in: PubMed
    Score: 0.011
  56. Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. Am J Ophthalmol. 2021 02; 222:328-339.
    View in: PubMed
    Score: 0.011
  57. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2021 05; 5(5):409-419.
    View in: PubMed
    Score: 0.011
  58. Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study. Br J Ophthalmol. 2021 08; 105(8):1111-1115.
    View in: PubMed
    Score: 0.011
  59. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Ophthalmol Retina. 2021 01; 5(1):60-70.
    View in: PubMed
    Score: 0.011
  60. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 08 01; 138(8):851-857.
    View in: PubMed
    Score: 0.011
  61. SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. Retina. 2020 Jun; 40(6):1029-1037.
    View in: PubMed
    Score: 0.011
  62. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021 02; 105(2):253-257.
    View in: PubMed
    Score: 0.011
  63. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 04 01; 138(4):341-349.
    View in: PubMed
    Score: 0.011
  64. THE TEXAS TACO TECHNIQUE FOR INTERNAL LIMITING MEMBRANE FLAP IN LARGE FULL-THICKNESS MACULAR HOLES: A Short-Term Pilot Study. Retina. 2020 Mar; 40(3):552-556.
    View in: PubMed
    Score: 0.011
  65. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology. 2020 06; 127(6):769-783.
    View in: PubMed
    Score: 0.011
  66. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. Am J Ophthalmol. 2020 01; 209:99-106.
    View in: PubMed
    Score: 0.010
  67. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
    View in: PubMed
    Score: 0.010
  68. Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1. Am J Ophthalmol. 2019 10; 206:154-160.
    View in: PubMed
    Score: 0.010
  69. Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration. Invest Ophthalmol Vis Sci. 2019 05 01; 60(6):2134-2139.
    View in: PubMed
    Score: 0.010
  70. Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. Am J Ophthalmol. 2019 10; 206:74-81.
    View in: PubMed
    Score: 0.010
  71. Real-World Trends in Intravitreal Injection Practices among American Retina Specialists. Ophthalmol Retina. 2019 08; 3(8):656-662.
    View in: PubMed
    Score: 0.010
  72. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 08; 126(8):1155-1170.
    View in: PubMed
    Score: 0.010
  73. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 06; 202:91-99.
    View in: PubMed
    Score: 0.010
  74. Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthalmol. 2019 01 01; 137(1):65-73.
    View in: PubMed
    Score: 0.010
  75. Predictors of Visual Acuity Outcomes Following Vitrectomy for Idiopathic Macular Hole. Ophthalmic Surg Lasers Imaging Retina. 2018 08 01; 49(8):566-570.
    View in: PubMed
    Score: 0.010
  76. Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2018 07 02; 59(8):3278-3285.
    View in: PubMed
    Score: 0.010
  77. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018 08; 125(8):1304-1306.
    View in: PubMed
    Score: 0.010
  78. Five-Year Outcomes of Surgically Treated Symptomatic Epiretinal Membranes With and Without Internal Limiting Membrane Peeling. Ophthalmic Surg Lasers Imaging Retina. 2018 05 01; 49(5):296-302.
    View in: PubMed
    Score: 0.010
  79. Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 08; 102(8):1066-1071.
    View in: PubMed
    Score: 0.010
  80. Identification of factors to increase efficacy of telemedicine screening for diabetic retinopathy in endocrinology practices using the Intelligent Retinal Imaging System (IRIS) platform. Diabetes Res Clin Pract. 2018 Jun; 140:265-270.
    View in: PubMed
    Score: 0.010
  81. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 07; 125(7):1054-1063.
    View in: PubMed
    Score: 0.009
  82. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. 2018 05; 125(5):683-690.
    View in: PubMed
    Score: 0.009
  83. Positive Visual Phenomena Following Implantation of the Argus II Retinal Prosthesis. Ophthalmic Surg Lasers Imaging Retina. 2017 12 01; 48(12):1022-1025.
    View in: PubMed
    Score: 0.009
  84. Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J Ophthalmol. 2017 Aug; 180:110-116.
    View in: PubMed
    Score: 0.009
  85. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017 02; 124(2):215-223.
    View in: PubMed
    Score: 0.009
  86. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. Ophthalmology. 2017 01; 124(1):74-81.
    View in: PubMed
    Score: 0.009
  87. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 2015 Oct; 50(5):373-7.
    View in: PubMed
    Score: 0.008
  88. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina. 2014 Sep; 34(9):1728-35.
    View in: PubMed
    Score: 0.007
  89. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014 Dec; 121(12):2432-42.
    View in: PubMed
    Score: 0.007
  90. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014 Sep; 121(9):1783-9.
    View in: PubMed
    Score: 0.007
  91. Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol. 2012 Jan; 153(1):162-6.e1.
    View in: PubMed
    Score: 0.006
  92. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol. 2003 Jun; 200(2):222-8.
    View in: PubMed
    Score: 0.003
  93. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer. 2003 Apr 07; 88(7):1065-70.
    View in: PubMed
    Score: 0.003
  94. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003 Feb 01; 21(3):473-82.
    View in: PubMed
    Score: 0.003
  95. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002 Jun; 1(5):459-68.
    View in: PubMed
    Score: 0.003
  96. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001 Nov 01; 61(21):7992-8.
    View in: PubMed
    Score: 0.003
  97. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001 Aug 15; 19(16):3660-8.
    View in: PubMed
    Score: 0.003
  98. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001 Jul 01; 61(13):5262-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.